Skip to main content
MedPath Trial logoMedPath TrialMedPath Trial Home
Clinical Trials/NCT00599469
NCT00599469UnknownPhase 1

Phase 1 Study to Determine the Efficacy of Using Far Infrared Radiation for the Treatment of Alzheimer's Disease.

GAAD Medical Research Institute Inc.2 sites in 1 country4 target enrollmentStarted: February 1, 2008Last updated:
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
Conditions

Trial Snapshot

Phase
Phase 1
Sponsor
Enrollment
4
Locations
2
Primary Endpoint
Management and Cure of Alzheimer's Disease
Study OverviewStudy DesignEligibility CriteriaOutcomesInvestigatorsSitesRecords & IdentifiersSimilar Trials

Study Overview

Brief Summary

Alzheimer's disease is a progressive and fatal brain disease. This study will investigate the use of far infrared radiation treatment for the disease.

Detailed Description

Alzheimer's destroys brain cells, causing problems with memory, thinking and behaviour severe enough to affect work, lifelong hobbies or social life. Alzheimer's gets worse over time and it is fatal.

Alzheimer's, which has no current cure, is the most common form of dementia. It is hereby postulated that far infrared radiation of the central nervous and endocrine systems will help with the management of the disease and possibly cure the disease.

Study Design

Study Type
Interventional
Allocation
Non Randomized
Intervention Model
Single Group
Primary Purpose
Treatment
Masking
None

Eligibility Criteria

Sex
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  • •People with Alzheimer's disease

Exclusion Criteria

  • Not provided

Outcomes

Primary Outcomes

Management and Cure of Alzheimer's Disease

Time Frame: 1 year

Secondary Outcomes

  • Management and Cure of Dementia(1 year)

Investigators

Sponsor
GAAD Medical Research Institute Inc.
Sponsor Class
Other

Study Sites (2)

Loading locations...

Similar Trials

Completed
Phase 1
Safety and Tolerability of AZD0530 (Saracatinib) in Alzheimer's DiseaseAlzheimer's Disease
NCT01864655Stephen M. Strittmatter24
Completed
Phase 2
Safety and Efficacy of MT-4666Alzheimer's Disease
NCT01764243Mitsubishi Tanabe Pharma Corporation450
Completed
Phase 2
Amyloid Imaging And Safety Study Of ACC-001 In Subjects With Early Alzheimer's DiseaseAlzheimer's Disease
NCT01227564Pfizer63
Completed
Phase 1
Bisnorcymserine in Healthy Adult VolunteersHealthy Volunteers
NCT01747213National Institute on Aging (NIA)75
Terminated
Phase 4
Functional Brain Imaging of Medication Treatment Response in Mild Alzheimer's Disease PatientsAlzheimer's Disease
NCT00369603Duke University4